12885_2022_9397_MOESM1_ESM.docx (49.92 kB)
Download fileAdditional file 1 of Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
journal contribution
posted on 2022-03-19, 04:30 authored by Federico Rojo, Esther Conde, Héctor Torres, Luis Cabezón-Gutiérrez, Dolores Bautista, Inmaculada Ramos, David Carcedo, Natalia Arrabal, J. Francisco García, Raquel Galán, Ernest NadalAdditional file 1: Table 1. Efficacy (median PFS and median OS) and costs associated with each first-line treatments.
History
References
- 10.1007/s12094-019-02218-4
- 10.1007/s12094-019-02218-4
- 10.1016/j.jtho.2016.03.022
- 10.1016/j.jtho.2016.03.022
- 10.1016/j.jtho.2019.07.005
- 10.1016/j.jtho.2019.07.005
- 10.1016/j.lungcan.2018.11.008
- 10.1016/j.lungcan.2018.11.008
- 10.1007/s40273-018-0625-6
- 10.1007/s40273-018-0625-6
- 10.2165/00019053-200017050-00006
- 10.2165/00019053-200017050-00006
